HALEON
NYSE HLN · Weybridge, United Kingdom
Works in ENT · GI & liver · Immunology · Infectious disease · Psychiatry · Respiratory
HALEON is a clinical trial sponsor based in Weybridge, United Kingdom, listed as NYSE HLN. It has 9 active clinical trials with 1,655 planned participants, across 6 therapeutic areas. Since 2021 it has completed 53 trials and stopped 0 early.
Trial track record · since 2021
Financials · NYSE HLN
Fundraising
Pipeline · 9 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
28 approved drug applications with a product on the market.
Questions about HALEON
HALEON is lead sponsor of 9 active clinical trials on ClinicalTrials.gov, with 1,655 planned participants, in ENT, GI & liver, Immunology, Infectious disease and other areas. Since 2021 it has completed 53 trials and stopped 0 early.
HALEON is based in Weybridge, United Kingdom and is listed as NYSE HLN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with HALEON; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Approve Suite is not affiliated with HALEON.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.